Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492580 · ClinicalTrials.gov registry record
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
A clinical trial of Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 714,582
- Enrollment target
- 1
- Study location
NCT03492580 is a study of Diabetes Mellitus, Type 2 and Cardiovascular Diseases that has completed, run by Janssen Research & Development. The registered enrollment target is 714,582 participants, above the 2,432-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (29282% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03492580, a study of Diabetes Mellitus, Type 2 and Cardiovascular Diseases, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 714,582 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed and reported in this study.
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG Dapagliflozin
- DRUG Canagliflozin
- DRUG Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- DRUG Glucagon-like Peptide-1 (GLP-1) Agonist
Study Locations (1)
New Jersey
- Janssen Investigative Site - Titusville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714,582 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2018-06-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03492580
The ClinicalTrials.gov registry entry for NCT03492580 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 714,582 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,432-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (29282% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 5 interventions - of which Empagliflozin is the first listed.
NCT03492580 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03492580 about?
NCT03492580 is a clinical study titled "A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease". The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 ...
What is the current status of trial NCT03492580?
This trial is currently completed. The enrollment target is 714,582 participants. The study started on 2018-02-22. Estimated completion is 2018-06-25.
What conditions does trial NCT03492580 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases.
What interventions are being tested in trial NCT03492580?
The interventions under investigation include: Empagliflozin (DRUG), Dapagliflozin (DRUG), Canagliflozin (DRUG), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (DRUG), Glucagon-like Peptide-1 (GLP-1) Agonist (DRUG).
Who is sponsoring clinical trial NCT03492580?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03492580 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.